AIM ImmunoTech Secures Europe UK Ampligen Patent

AIM ImmunoTech reports expanded patent protection for Ampligen in Europe and the United Kingdom covering its use for Long COVID, with exclusivity through June 2041 and the nine-month opposition period ending August 25, 2026 without filings. The European/UK coverage includes multiple countries and specifies diverse dosing and delivery methods for tdsRNA-based Ampligen as a treatment for Long COVID. In parallel, the company notes a newly issued U.S. patent protecting Ampligen in combination with pembrolizumab (Keytruda) for cancer, extending protection through December 2039 and reinforcing a broad oncology IP estate. Additional patents in the U.S., Europe, and Japan further support Ampligen in combination with PD-1/PD-L1 inhibitors across cancers such as pancreatic, skin, colorectal, ovarian, breast, and others. Company leadership emphasizes that these patents build a durable, durable intellectual property framework around Ampligen’s potential in cancer immunotherapy and other indications. Taken together, AIM’s patent activity signals a strategic push to secure multi-market, multi-indication protection for Ampligen as it pursues late-stage oncology development and exploration of long-COVID therapies.